Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington: American Psychiatric Publishing, 2000
   Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. Morb Mortal Wkly Rep 2010;59:1439-43
   PubMedGoogle Scholar
• Castells X, Ramos-Quiroga JA, Bosch R, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2011;6:CD007813
   PubMedGoogle Scholar
• Management of attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Scottish Intercollegiate Guidelines Network, 2009. Available at: http://www.sign.ac.uk/guidelines/fulltext/112/index.html [Last accessed 7 March 2014]
   Google Scholar
• Coghill D, Soutullo C, d’Aubuisson C, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health 2008;2:31
   PubMedGoogle Scholar
• Biederman J, Wilens TE, Mick E, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998;44:269-73
   PubMed Web of Science ®Google Scholar
• DiScala C, Lescohier I, Barthel M, et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998;102:1415-21
   PubMed Web of Science ®Google Scholar
• Jensen PS, Shervette RE 3rd, Xenakis SN, et al. Psychosocial and medical histories of stimulant-treated children. J Am Acad Child Adolesc Psychiatry 1988;27:798-801
   PubMed Web of Science ®Google Scholar
• Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995;7:373-8
   PubMedGoogle Scholar
• Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997;36:37-44
   PubMed Web of Science ®Google Scholar
• Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010;19:83-105
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE Clinical Guideline 72. September 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG072NiceGuidelineV2.pdf [Last accessed 7 March 2014]
   Google Scholar
• Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents [TA98]. National Institute for Health and Clinical Excellence, 2006. Available at: http://www.nice.org.uk/TA98 [Last accessed 7 March 2014]
   Google Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15:476-95
   PubMed Web of Science ®Google Scholar
• Lisdexamfetamine [package insert]. Available at: http://www.medicines.org.uk/emc/medicine/27442/SPC/Elvanse+30mg%2c+50mg+%26+70mg+Capsules%2c+hard/#PHARMACOKINETIC_PROPS [Last accessed 2 January 2014]
   Google Scholar
• Coghill D, Banaschewski T, Lecendreux M, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2013;23:1208-18
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50:395-405
   PubMed Web of Science ®Google Scholar
• Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-63
   PubMed Web of Science ®Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010;19:353-64
   PubMed Web of Science ®Google Scholar
• Single technology appraisal: specification for manufacturer/sponsor submission of evidence. National Institute for Health and Care Excellence, June 2012. Available at: http://www.nice.org.uk/media/D54/6E/SpecificationForManufacturerSponsorSubmissionOfEvidenceJune2012.doc [Last accessed 3 December 2013]
   Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, et al. The ADHD Rating Scale-IV: Checklist, Norms, and Clinical Interpretation. New York: Guilford Press, 1998
   Google Scholar
• Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 2001;5:107-15
   Google Scholar
• Guy W (ed.) Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976:218-22
   Google Scholar
• Whitehead A. Meta-analysis of Controlled Clinical Trials. Chichester: John Wiley & Sons Ltd, 2002
   Google Scholar
• Jones B, Roger J, Lane PW, et al; PSI Health Technology Special Interest Group, Evidence Synthesis sub-team. Statistical approaches for conducting network meta-analysis in drug development. Pharm Stat 2011;10:523-31
   PubMed Web of Science ®Google Scholar
• Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-7
   PubMed Web of Science ®Google Scholar
• CRD’s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, 2009. Available at: http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf [Last accessed 7 March 2014]
   Google Scholar
• Sharp WS, Walter JM, Marsh WL, et al. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 1999;38:40-7
   PubMed Web of Science ®Google Scholar
• Abikoff HB, Vitiello B, Riddle MA, et al. Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007;17:581-92
   PubMed Web of Science ®Google Scholar
• Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008;121:e314-20
   PubMed Web of Science ®Google Scholar
• Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5:833-41
   PubMedGoogle Scholar
• Dell’Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol 2009;19:822-34
   PubMed Web of Science ®Google Scholar
• Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006;15:450-9
   PubMed Web of Science ®Google Scholar
• Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 2006;16:441-55
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Findling RL, Swanson JM; ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109:E39
   PubMed Web of Science ®Google Scholar
• Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005;22:498-512
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41:776-84
   PubMed Web of Science ®Google Scholar
• Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry 2010;19:57-66
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901
   PubMed Web of Science ®Google Scholar
• Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose–response study. Pediatrics 2001;108:E83
   PubMed Web of Science ®Google Scholar
• Pliszka SR, Browne RG, Olvera RL, et al. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2000;39:619-26
   PubMed Web of Science ®Google Scholar
• Steele M, Weiss M, Swanson J, et al. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006;13:e50-62
   PubMedGoogle Scholar
• Takahashi M, Takita Y, Yamazaki K, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:341-50
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007;41:222-30
   PubMed Web of Science ®Google Scholar
• Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:647-55
   PubMed Web of Science ®Google Scholar
• Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2004;43:1406-14
   PubMed Web of Science ®Google Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:883-92
   PubMed Web of Science ®Google Scholar
• Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008;165:721-30
   PubMed Web of Science ®Google Scholar
• Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009;48:723-33
   PubMed Web of Science ®Google Scholar
• Gau SS, Huang YS, Soong WT, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007;17:447-60
   PubMed Web of Science ®Google Scholar
• Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Vaughan BS, Stoner JA, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics 2011;127:e862-8
   PubMed Web of Science ®Google Scholar
• Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 2009;25:2745-54
   PubMed Web of Science ®Google Scholar
• Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:149-59
   PubMed Web of Science ®Google Scholar
• Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90
   PubMed Web of Science ®Google Scholar
• Setyawan J, Hodgkins P, Guérin A, et al. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ 2013;16:962-75
   PubMedGoogle Scholar